Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?

Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.Eli Lilly (LLY -0.13%) stock is already up by about 90% over the past year, and it could climb even higher. BMO Capital analyst Evan Seigerman recently raised his price target to $1,001 per share, which implies a gain of about 24% from recent prices.Seigerman recently noted that soaring demand for Eli Lilly's weight management drug, Zepbound, is outpacing supply. The company plans to improve on the ...